Cityhälsan Centrum
Norrköping, Östergötland County, 60239, Sweden
NCT Number: NCT05661721
Out-of-office blood pressure is more strongly associated with cardiovascular risk than office blood pressure. Licorice is known to raise blood pressure, but no previous studies have measured the effects on home blood pressure. The aim of this study is to analyze the association between licorice intake and home blood pressure.
Looking for future studies?
Notify Me18 year–30 year
All sexes
Interventional
Not applicable
Norrköping, Östergötland County, 60239, Sweden
Healthy volunteers will be invited to participate in a randomized, non-blinded, cross-over study. Participants will be randomized to either of two groups with a 1:1 allocation ratio, stratified by sex. Intervention will be sweet licorice and control will be salty licorice. A run-in period of 1 week will be followed by a 2-week intervention/control, a 2-week washout period, another 2-week control/intervention period and again a 2-week washout period. Home blood pressure will be measured continuously, and blood samples (including potassium and aldosterone) will be collected every two weeks. Analyses will be made comparing baseline characteristics of the two groups, intervention/control and washout period results of the two groups to look for potential carry-over effects, and finally comparing intervention and washout period results respectively to the baseline data to look for the effects of licorice.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Ecologic, vegan and gluten free, low-sodium sweet licorice pastilles made from Glycyrrhiza glabra, with a manufacturer specified content of 4% sugars, 2% glycyrrhizin and 0.03% salt, will be used as intervention. The exact glycyrrhizin content will be determined before the study begins, and participants will be instructed to consume a daily licorice dose that is equivalent to 100 mg of glycyrrhizin.
Other names: Glycyrrhiza glabra
A vegan and gluten free salty licorice without glycyrrhizin, flavored with ammonium chloride, with a manufacturer specified content of 0% sugars and 0.05% salt, will be used as control. The amount of salty licorice will be the same as for sweet licorice, and thus determined after the glycyrrhizin content analysis of the sweet licorice.
Time frame: Mean at the end of 14 days of intervention compared with mean during run-in period
Systolic home blood pressure (mmHg)
Time frame: Mean at the end of 14 days of intervention compared with mean during run-in period
Diastolic home blood pressure (mmHg)
Time frame: Mean at the end of 14 days of intervention compared with mean during run-in period
Body weight (kg)
Time frame: Mean at the end of 14 days of intervention compared with mean during run-in period
Plasma potassium (mmol/L)
Time frame: Mean at the end of 14 days of intervention compared with mean during run-in period
Plasma sodium (mmol/L)
Time frame: Mean at the end of 14 days of intervention compared with mean during run-in period
Plasma renin (mIU/L)
Time frame: Mean at the end of 14 days of intervention compared with mean during run-in period
Serum aldosterone (μmol/L)
Linkoeping University
Other Gov
Licorice and Home Blood Pressure: a Randomized Crossover Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06461273
Behavior, Body Weight
Newark, New Jersey, United States
View Trial DetailsNCT05086523
Cardiovascular Diseases, Essential Hypertension
Prague, Czechia
View Trial DetailsNCT06501586
Cardiovascular Diseases, Essential Hypertension
Beijing, Beijing Municipality, China
View Trial DetailsNCT03480217
Cardiovascular Diseases, Essential Hypertension
New York, United States
View Trial Details